Aficamten

Chemical formula: C₁₈H₁₉N₅O₂ Molecular mass: 337.154 g/mol PubChem compound: 139331495

Therapeutic indications

Aficamten is indicated for:

Obstructive hypertrophic cardiomyopathy (oHCM)

Population group: only adults (18 years old or older)

Aficamten is indicated for the treatment of symptomatic (New York Heart Association, NYHA, class II-III) obstructive hypertrophic cardiomyopathy (oHCM) in adult patients.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

5 mg initial dose with subsequent increase every 2-8 weeks by 5 mg until maintenance dose or maximum dose of 20 mg is reached

Contraindications

Aficamten is contraindicated in the following cases:

Moderate CYP2C9 inhibitors that are also moderate-to-strong inhibitors of CYP2D6 or CYP3A

Moderate CYP2C9 inhibitors and additionally at least one of

Moderate CYP2D6 inhibitors
Strong CYP2D6 inhibitors
Moderate CYP3A4 inhibitors
Cytochrome P-450 CYP3A5 moderate inhibitors
Strong CYP3A4 inhibitors
Cytochrome P-450 CYP3A5 strong inhibitors

Strong CYP3A4 inducers that are also moderate CYP2C9 inducers

Strong potency CYP3A4 inducers and additionally CYP2C9 inducers

< Previous: Overview

Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.